U.S., March 27 -- ClinicalTrials.gov registry received information related to the study (NCT06896422) titled 'Randomized Trial of Glutathione with Anti-PD-1 and Chemotherapy in Advanced NSCLC' on March 20.
Brief Summary: Chemotherapeutic agents exert significant immunomodulatory effects by influencing tumor-infiltrating immune cells. However, the sequence and combination of chemotherapy regimens differentially modulate immune cell dynamics, ultimately impacting treatment efficacy and patient survival. Glutathione, a critical bioactive molecule, demonstrates broad potential in tumor immunotherapy. Through mechanisms such as scavenging free radicals, modulating immune cell proliferation and differentiation, and regulating cytokine expression...